Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from Blueprint Medicines, Exelixis, and Lilly.

Addressing Clinical Gaps in Thyroid Cancer Management: New Agents, New Testing Paradigms, and Methods to Facilitate Multidisciplinary Care and Coordination

Release Date: July 9, 2021
Expiration Date: July 9, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts who discuss targeted therapy and genetic testing in the treatment of thyroid cancer. Patient case examples are used to present the most recent evidence for optimizing care for RAI-refractory differentiated thyroid cancer (DTC) and improving strategic decision-making in advanced medullary thyroid cancer (MTC). Considerable progress has been made in understanding the molecular mechanisms of thyroid cancer in the past 20 years, including identification the role of telomerase reverse transcriptase (TERT) promoter mutations in DTC progression, as well as the impact of the RET gene in papillary thyroid carcinoma (PTC) and MTC oncogenesis. Major advances in recent years have broadened the therapies available in the treatment of radioactive iodine (RAI)-refractory DTC as well as MTC and include multikinase inhibitors as well as two novel selective RET inhibitors.

This educational activity is an archive of the live virtual symposium held on June 15, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Blueprint Medicines, Exelixis, and Lilly.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward endocrinologists and radiation, surgical, and medical oncologists interested in the treatment of thyroid cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with thyroid cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

Explain the impact of genetic testing in diagnosis and treatment decision-making in thyroid cancer
Evaluate the clinical profiles of current and emerging targeted therapies for the treatment of patients with RAI-refractory DTC and advanced MTC
Translate results from landmark trials evaluating targeted agents in thyroid cancer into personalized treatment plans with a focus on multidisciplinary care optimization
Implement proactive strategies to identify and manage treatment-related toxicities in patients with RAI-refractory DTC and advanced MTC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Program Chair

Marcia S. Brose, MD, PhD
Professor of Medicine and Otorhinolaryngology
Head and Neck Surgery
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Grant/Research Support: Bayer Healthcare, Eisai, Loxo Oncology, Blueprint Medicines, Novartis Pharmaceuticals, Exelixis; Consultant: Bayer HealthCare, Exelixis, Eisai, Loxo Oncology; Other: Honorarai Bayer Healthcare, Eisai

Faculty

Jill Gilbert, MD
Professor of Medicine (Hematology/Oncology)
Director, Hematology/Oncology Fellowship Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Grant/Research Support: Exelixis; Consultant: Exelixis, Bayer

Jennifer JD Morrissette, PhD
Associate Professor of Clinical Pathology and Laboratory Medicine
Clinical Director, Center for Personalized Diagnostics
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Disclosures: Consultant: Novartis Pharmaceuticals, Bayer Healthcare; Speakers’ Bureau: National Comprehensive Cancer Network; Stock/Shareholder: Thermo Fisher Scientific

Francis Paul Worden, MD
Clinical investigator
Multidisciplinary Head and Neck Oncology
Multidisciplinary Lung Cancer
University of Michigan Rogel Cancer Center
Ann Arbor, MI

Disclosures: Grant/Research Support: Merck, BMS, Bayer, CUE, Lilly; Consultant: Merck, BMS, Eisai, Exelexis

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.